| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
|
N Engl J Med
|
2010
|
36.78
|
|
2
|
ROS1 rearrangements define a unique molecular class of lung cancers.
|
J Clin Oncol
|
2012
|
9.76
|
|
3
|
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.
|
Lancet Oncol
|
2012
|
8.64
|
|
4
|
Crizotinib in ROS1-rearranged non-small-cell lung cancer.
|
N Engl J Med
|
2014
|
6.95
|
|
5
|
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.
|
Lancet Oncol
|
2011
|
6.69
|
|
6
|
Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.
|
N Engl J Med
|
2010
|
6.28
|
|
7
|
Acquired resistance to crizotinib from a mutation in CD74-ROS1.
|
N Engl J Med
|
2013
|
3.42
|
|
8
|
MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.
|
J Clin Oncol
|
2011
|
3.27
|
|
9
|
CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib.
|
J Clin Oncol
|
2011
|
3.00
|
|
10
|
Identifying and targeting ROS1 gene fusions in non-small cell lung cancer.
|
Clin Cancer Res
|
2012
|
2.66
|
|
11
|
Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer.
|
J Thorac Oncol
|
2012
|
2.47
|
|
12
|
Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.
|
J Clin Oncol
|
2015
|
2.26
|
|
13
|
Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.
|
J Thorac Oncol
|
2011
|
2.19
|
|
14
|
Novel targets in non-small cell lung cancer: ROS1 and RET fusions.
|
Oncologist
|
2013
|
2.04
|
|
15
|
Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology.
|
Oncologist
|
2012
|
1.88
|
|
16
|
HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer.
|
Clin Cancer Res
|
2009
|
1.57
|
|
17
|
Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond.
|
Drug Des Devel Ther
|
2011
|
1.57
|
|
18
|
Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities.
|
Ther Adv Med Oncol
|
2011
|
1.55
|
|
19
|
HGF rescues colorectal cancer cells from EGFR inhibition via MET activation.
|
Clin Cancer Res
|
2010
|
1.50
|
|
20
|
ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.
|
Clin Adv Hematol Oncol
|
2014
|
1.48
|
|
21
|
Targeting the HGF/Met signaling pathway in cancer therapy.
|
Expert Opin Ther Targets
|
2012
|
1.45
|
|
22
|
Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer.
|
Onco Targets Ther
|
2014
|
1.19
|
|
23
|
Molecular pathways and therapeutic targets in lung cancer.
|
Oncotarget
|
2014
|
1.16
|
|
24
|
Targeting MET Amplification as a New Oncogenic Driver.
|
Cancers (Basel)
|
2014
|
1.11
|
|
25
|
Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer.
|
Transl Lung Cancer Res
|
2015
|
1.07
|
|
26
|
The potential for crizotinib in non-small cell lung cancer: a perspective review.
|
Ther Adv Med Oncol
|
2011
|
1.05
|
|
27
|
Asymptomatic profound sinus bradycardia (heart rate ≤45) in non-small cell lung cancer patients treated with crizotinib.
|
J Thorac Oncol
|
2011
|
1.04
|
|
28
|
Targeting the HGF-cMET Axis in Hepatocellular Carcinoma.
|
Int J Hepatol
|
2013
|
0.99
|
|
29
|
Experience with targeted next generation sequencing for the care of lung cancer: insights into promises and limitations of genomic oncology in day-to-day practice.
|
Cancer Treat Commun
|
2015
|
0.99
|
|
30
|
Clinicopathologic analysis of ROS1-rearranged non-small-cell lung cancer and proposal of a diagnostic algorithm.
|
J Thorac Oncol
|
2013
|
0.97
|
|
31
|
Molecularly targeted therapies in non-small-cell lung cancer annual update 2014.
|
J Thorac Oncol
|
2015
|
0.97
|
|
32
|
Lung cancer in the era of precision medicine.
|
Clin Cancer Res
|
2015
|
0.96
|
|
33
|
Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma.
|
J Cancer Res Clin Oncol
|
2014
|
0.95
|
|
34
|
A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments.
|
Carcinogenesis
|
2013
|
0.94
|
|
35
|
Favorable response to crizotinib in three patients with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion-type oncogene-positive non-small cell lung cancer.
|
Cancer Sci
|
2011
|
0.92
|
|
36
|
Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-Small Cell Lung Cancer Globally?
|
Front Oncol
|
2014
|
0.92
|
|
37
|
c-Met as a Target for Personalized Therapy.
|
Transl Oncogenomics
|
2015
|
0.92
|
|
38
|
Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors.
|
Clin Epidemiol
|
2014
|
0.92
|
|
39
|
Characteristics and follow-up of postmarketing studies of conditionally authorized medicines in the EU.
|
Br J Clin Pharmacol
|
2016
|
0.91
|
|
40
|
Personalized treatment strategies for non-small-cell lung cancer in Chinese patients: the role of crizotinib.
|
Onco Targets Ther
|
2015
|
0.90
|
|
41
|
Personalizing therapy in advanced non-small cell lung cancer.
|
Semin Respir Crit Care Med
|
2013
|
0.89
|
|
42
|
Personalized medicine and treatment approaches in non-small-cell lung carcinoma.
|
Pharmgenomics Pers Med
|
2012
|
0.89
|
|
43
|
Crizotinib: A comprehensive review.
|
South Asian J Cancer
|
2013
|
0.85
|
|
44
|
Targeting genomic alterations in squamous cell lung cancer.
|
Front Oncol
|
2013
|
0.85
|
|
45
|
Activation of RAS family members confers resistance to ROS1 targeting drugs.
|
Oncotarget
|
2015
|
0.83
|
|
46
|
Testing for ROS1 in non-small cell lung cancer: a review with recommendations.
|
Virchows Arch
|
2016
|
0.83
|
|
47
|
ALK Inhibitors, a Pharmaceutical Perspective.
|
Front Oncol
|
2012
|
0.82
|
|
48
|
The democratization of the oncogene.
|
Cancer Discov
|
2014
|
0.81
|
|
49
|
Activated RET and ROS: two new driver mutations in lung adenocarcinoma.
|
Transl Lung Cancer Res
|
2013
|
0.81
|
|
50
|
Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling.
|
Clin Lung Cancer
|
2015
|
0.80
|
|
51
|
Understanding and Targeting MET Signaling in Solid Tumors - Are We There Yet?
|
J Cancer
|
2016
|
0.79
|
|
52
|
New targeted treatments for non-small-cell lung cancer - role of nivolumab.
|
Biologics
|
2016
|
0.79
|
|
53
|
Responses to crizotinib in a patient with c-ros oncogene 1, receptor tyrosine kinase-positive advanced lung adenocarcinoma: A case report.
|
Oncol Lett
|
2014
|
0.78
|
|
54
|
The minority report: targeting the rare oncogenes in NSCLC.
|
Curr Treat Options Oncol
|
2014
|
0.78
|
|
55
|
MET inhibitors in combination with other therapies in non-small cell lung cancer.
|
Transl Lung Cancer Res
|
2012
|
0.78
|
|
56
|
Crizotinib induces autophagy through inhibition of the STAT3 pathway in multiple lung cancer cell lines.
|
Oncotarget
|
2015
|
0.78
|
|
57
|
Detection of lung adenocarcinoma with ROS1 rearrangement by IHC, FISH, and RT-PCR and analysis of its clinicopathologic features.
|
Onco Targets Ther
|
2015
|
0.77
|
|
58
|
Current and future treatment of anaplastic lymphoma kinase-rearranged cancer.
|
World J Clin Oncol
|
2015
|
0.76
|
|
59
|
ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance.
|
Oncotarget
|
2016
|
0.76
|
|
60
|
MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-Life.
|
Clin Cancer Res
|
2016
|
0.76
|
|
61
|
Has MET met its match?
|
Ann Transl Med
|
2016
|
0.76
|
|
62
|
Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer.
|
Drug Des Devel Ther
|
2015
|
0.75
|
|
63
|
Pharmacokinetic profiles of significant adverse events with crizotinib in Japanese patients with ABCB1 polymorphism.
|
Cancer Sci
|
2016
|
0.75
|
|
64
|
MET exon 14 deletion (METex14): finally, a frequent-enough actionable oncogenic driver mutation in non-small cell lung cancer to lead MET inhibitors out of "40 years of wilderness" and into a clear path of regulatory approval.
|
Transl Lung Cancer Res
|
2015
|
0.75
|